Summary
The aim of this study was to assess the cost-effectiveness of combination chemotherapy with paclitaxel/cisplatin, compared with standard etoposide/cisplatin in patients with advanced non-small cell lung cancer (NSCLC). We obtained the primary survival and resource utilization data from a large three-arm randomized trial comparing: paclitaxel 135 mg m–2 by 24-h intravenous (i.v.) infusion + cisplatin; paclitaxel 250 mg m–2 by 24-h i.v. infusion + cisplatin + granulocyte colony-stimulating factor (G-CSF); and standard etoposide/cisplatin in patients with stage IIIb or IV NSCLC. We also modelled the regimens with paclitaxel 135 mg m–2 + cisplatin administered as an outpatient by 3-h infusion, as clinical data suggest that this is equivalent to 24-h infusion. We collected costing data from the Ottawa Regional Cancer Centre and applied it to the resources consumed in the randomized trial. We integrated these data into the Statistics Canada POpulation HEalth Model (POHEM), which generated hypothetical cohorts of patients treated with each regimen. The POHEM model assigned diagnostic work-up, treatment, disease progression and survival characteristics to each individual in these cohorts and tabulated the costs associated with each. We did sensitivity analyses around the costs of chemotherapy and its administration, and the survival differences between the two regimens. All costs are in 1997 Canadian dollars ($1.00 Canadian ~ £0.39 sterling). The perspective is that of the Canadian health care system. In the trial, the two paclitaxel-containing arms had almost identical survival curves with a median survival of 9.7 months compared with 7.4 months for etoposide/cisplatin. As administered in the trial, paclitaxel/cisplatin cost $76 370 per life-year gained (LYG) and paclitaxel/cisplatin/G-CSF $138 578 per LYG relative to etoposide/cisplatin. However, when modelled as an outpatient 3-h infusion, paclitaxel/cisplatin was moderately cost-effective at $30 619 per LYG. When compared with historical controls treated with best supportive care, this regimen of paclitaxel/cisplatin cost $4539 per LYG. Assuming a 3-h paclitaxel infusion yields the same survival advantage as the 24-h infusion did in the randomized trial, paclitaxel/cisplatin is a cost-effective improvement over standard etoposide/cisplatin for patients with advanced non-small cell lung cancer.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bonomi, P., Kim, K., Chang, A. & Johnson, D. (1996). Phase III trial comparing etoposide (E) cisplatin (C) versus taxol (T) with cisplatin-G-CSF (G) versus taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) trial. Proc Am Soc Clin Oncol 15: 1145 (Abstract)
Bonomi, P., Kyungmann, K., Kusler, J. & Johnson, D. (1997). Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer. Oncology 11: 9–10.
Canadian Coordinating Office for Health Technology, Assessment (1997). The Use of G-CSF in the Prevention of Febrile Neutropenia. Canadian Coordinating Office for Health Technology Assessment (CCOHTA): Ottawa
Chang, A. Y., Kim, K., Glick, J., Anderson, T., Karp, D. & Johnson, D. (1993). Phase II study of Taxol, Merbarone, and Piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85: 388–394.
Detsky, A. & Naglie, I. (1990). A clinician’s guide to cost-effectiveness analysis. Ann Int Med 113: 147–154.
Earle, C. C. & Evans, W. K. (1997). A comparison of the cost of paclitaxel versus best supportive care in stage IV non-small cell lung cancer. Cancer Prev Control 1: 282–288.
Evans, W. K. (1996). An estimate of the cost effectiveness of gemcitabine in stage IV non-small cell lung cancer. Semin Oncol 23: 82–89.
Evans, W. K. & Chevalier, T. (1996). The cost-effectiveness of Navelbine alone or in combination with cisplatin in comparison to standard therapies in stage IV non-small cell lung cancer. Eur J Cancer 32A: 2249–2255.
Evans, W. K., Burpee, C., Skinn, B., Stewart, D. J., Stapleton, J., Armstrong, J., Pollock, D., Goss, G. & Logan, D. (1993). An evaluation of the costs of outpatient chemotherapy administration for small cell lung cancer. Can J Oncol 3: 225–232.
Evans, W. K., Will, B. P., Berthelot, J-M & Wolfson, M. C. (1995a). Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model. Can J Oncology 5: 408–419.
Evans, W. K., Will, B. P., Berthelot, J-M & Wolfson, M. C. (1995b). Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. Br J Cancer 72: 1270–1277.
Evans, W. K., Will, B. P., Berthelot, J-M & Wolfson, M. C. (1995c). The cost of managing lung cancer in Canada. Oncology 9: 147–153.
Evans, W. K., Earle, C. C., Berthelot, J-M, Will, B. P., Houle, C. & Flanagan, B. (1997a). The cost and cost-effectiveness of small cell lung cancer treatment in Canada. Proc Am Soc Clin Oncol 16: 1503 (Abstract)
Evans, W. K., Will, B. P., Berthelot, J-M & Earle, C. C. (1997b). The cost of combined modality interventions for stage III non-small cell lung cancer. J Clin Oncol 15: 3038–3048.
Fossella, F., Lee, J. & Murphy, W. (1994). Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 12: 1238–1244.
Francis, P., Rigas, J., Kris, M., Pisters, K. M. W., Orazem, J. P., Wooley, K. J. & Heelon, R. T. (1994). Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 12: 1232–1237.
Gatzemeier, U., von Pawal, J., Gottfried, M., ten Velde, G. P. M., Mattson, K., DeMarinis, F., Harper, P., Salvati, F., Robinet, G. & Lucenti, A. (1998). Phase III comparative study of high-dose cisplatin (HD-CIS) versus a combination of paclitaxel (TAX) and cisplatin (CIS) in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17:
Giaccone, G., Splinter, T. A. W., Debruyne, C., Kho, G. S., Lianes, P., Van Zandwijk, N., Pennucci, M. C., Scagliotti, G., van Meerbeeckm, J., van Hoesel, Q., Curran, D. S. T. & Postmus, P. E. (1998). Randomized study of paclitaxel–cisplatin versus cisplatin–teniposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 16: 2133–2141.
Goss, G. D., Dahrouge, S. & Lochrin, C. A. (1996). Recent advances in the treatment of non-small cell lung cancer. Anti-Cancer Drugs 7: 363–385.
Hainsworth, J., Raefsky, E., Thomas, M. & Greco, F. (1995). Paclitaxel administered by 1-hour infusion: Phase I/II study comparing two schedules of administration. Proc Am Soc Clin Oncol 14: 376 (Abstract)
Jaakkimainen, L., Goodwin, P. J. & Pater, J. (1990). Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small cell lung cancer. J Clin Oncol 8: 1301–1309.
Laupacis, A., Feeny, D., Detsky, A. & Tugwell, P. (1992). How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 146: 473–481.
Mamounas, E. P., Brown, A., Smith, R. D., Lembersky, B., Fisher, B., Wickerham, D. L., Wolmark, N., Atkins, J., Shibata, H. & Baez, L. (1998). Effect of Taxol duration of infusion in advanced breast cancer (ABC): results from NSABP B-26 trial comparing 3- to 24-h infusion of high dose Taxol. Proc Am Soc Clin Oncol 17: (Abstr 389)
Murphy, W. K., Fossella, F. W., Winn, R. J., Shin, D. M., Hynes, H. E., Gross, H. M., Davilla, E., Leimert, J., Dhingra, H., Raber, M. N., Krakoff, I. H. & Hong, W. K. (1993). Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85: 384–388.
Non-small Cell Lung Cancer Collaborative, Group (1995). Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311: 899–909.
Parker, S., Tong, T., Bolden, S. & Wingo, P. (1996). Cancer Statistics, 1996. CA Cancer J Clin 65: 5–27.
Raby, B., Pater, J. & Mackillop, W. (1995). Does knowledge guide practice? Another look at the management of non-small-cell lung cancer. J Clin Oncol 13: 1904–1911.
Rowinsky, E. K. & Donehower, R. C. (1995). Drug therapy: paclitaxel (Taxol). N Engl J Med 332: 1004–1014.
Steward, W. & Dunlop, D. (1995). New drugs in the treatment of non-small cell lung cancer. Ann Oncol 6: S49–S54.
Thatcher, N., Ranson, M., Lee, M., Niven, R. & Anderson, H. (1995). Chemotherapy in non-small cell lung cancer. Ann Oncol 6: S83–S95.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Earle, C., Evans, W. Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer. Br J Cancer 80, 815–820 (1999). https://doi.org/10.1038/sj.bjc.6690426
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690426
Keywords
This article is cited by
-
Ultrastructural damage in lung tissues in rats treated with doxorubicin and paclitaxel
Advances in Therapy (2008)
-
Economics of the clinical management of lung cancer in France: an analysis using a Markov model
British Journal of Cancer (2004)
-
The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE)
British Journal of Cancer (2002)
